Orum Therapeutics demonstrates the potential of “Targeted Protein Degradation (TPD²)" technology.
Orum Therapeutics, led by CEO Sung-Joo Lee, made a significant announcement on November 6th, confirming the signing of an agreement to transfer the '카지노 사이트6151 (development code name)' program to Bristol Myers Squibb (BMS).
In this strategic acquisition, BMS will provide Orum Therapeutics with an upfront payment of 0 million in exchange for securing the 카지노 사이트6151 program. This agreement encompasses additional milestone-based payments, ultimately totaling 0 million for Orum Therapeutics. Specific financial terms beyond this were not disclosed.
카지노 사이트6151 represents a groundbreaking anti-CD33 antibody-based GSPT1 protein degrader drug, having received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA). Its intended use is in the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MSD).
Sung-Joo Lee, CEO of Orum Therapeutics, expressed his enthusiasm, saying, "BMS is a global leader in the field of anticancer drugs, known for their expertise in protein degradation. This agreement serves as a testament to the potential of our proprietary 'Dual-Precision Targeted Protein Degradation (TPD²)' technology."
Lee continued, emphasizing the company's pioneering approach to delivering target protein degrader drugs to cancer cells in the form of antibody-drug conjugates (ADC). This method widens the therapeutic window and maximizes the potential of targeted protein degraders. Lee stated, "We are highly optimistic about BMS's stewardship of the 카지노 사이트6151 program and its potential to become a transformative treatment for cancer patients."
In facilitating this agreement, financial advisory services were provided by Perella Weinberg Partners, with legal counsel offered by Sterne Kessler Goldstein & Fox and Skadden, Arps, Slate, Meagher & Flom LLP.